Furthermore, CIK therapy plus anti-PD-1 treatment was shown to be a feasible combination therapy method to promote the anti-tumor response of CIK cells and inhibit tumor progression, especially for NSCLC patients with dysfunctional and low proportion of CD4+ T cells in their peripheral blood. The gene discussed is CD4; the disease is non-small cell lung carcinoma.